Technical Principle
By placing electrodes around the hypertrophic gland at the urethra and bladder neck, and delivering pulsed electric field ablation, the ablated cells undergo apoptosis and necrosis within 7-14 days. These cells are subsequently phagocytosed, thereby relieving compression of the urethra and bladder neck, which ultimately improves voiding dysfunction.

Ablation Characteristics
1. Non-thermal ablation : Ensures no thermal damage to the urethra/rectum
2. Highly tissue-selective : Only ablates glandular tissue while sparing erectile nerves and blood vessels.
3. Ultra-minimally invasive : Causes minimal trauma, with only a few 1mm puncture sites in the perineal area.
Applications
The product is intended for use in medical institutions to relieve symptoms of urinary obstruction in male patients with benign prostatic hyperplasia (BPH) who meet the following criteria: age ≥50 years, International Prostate Symptom Score (IPSS) ≥12, and prostate volume ≥30 cm³.
Product Advantages
Product Configuration
| No. | Component | Component Model Number |
|---|---|---|
| 1 | Rack-Mounted Main Control Unit (with Integrated Display) | IRE-BPH-01-A |
| 2 | Bottom Rack Space for Main Control Unit | IRE-BPH-01-B |
| 3 | Footswitch | HRF-M5Y/A |
| 4 | Inter-cabinet signal cable | PT-CNT-36A |
| 5 | Inter-cabinet power cable | / |
| 6 | AC power cable | / |











